April 12, 2026 10:10 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Legendary singer Asha Bhosle suffers cardiac arrest, hospitalised | Big boost to India–Mauritius ties: S. Jaishankar hands over 90 e-buses | Middle East tension: Iranian delegation arrives in Islamabad for major talks, 10,000 security personnel deployed | Ranveer Singh visits RSS HQ amid Dhurandhar 2 success, triggers speculation | ED raids ex-Bengal minister Partha Chatterjee; SSC scam resurfaces ahead of polls | Amit Shah promises UCC, ₹3,000 aid per month for women and youth in BJP’s Bengal manifesto | Nitish Kumar takes Rajya Sabha oath; power shift looms in Bihar | Sting video fallout: AIMIM snaps electoral ties with Humayun Kabir in Bengal | Israel says Hezbollah chief’s nephew-cum-secretary killed in Beirut strikes last night | Modi slams TMC on trade, fisheries at Haldia; vows 7th pay commission for govt employees
Covid-19 Vaccine

Vaccine by itself will not end coronavirus pandemic: WHO Chief

| @indiablooms | Nov 17, 2020, at 04:20 am

Geneva/IBNS: World Health Organization (WHO) chief Tedros Adhanom Ghebreyesus on Monday said a vaccine would not by itself stop the coronavirus pandemic and cannot replace the other tools.

In a tweet, he said: A vaccine on its own will not end the COVID19 pandemic. We will still need to continue."

"Since the beginning of the COVID19 pandemic, we knew that a vaccine would be essential for bringing the pandemic under control. But it’s important to emphasise that a vaccine will complement the other tools we have, not replace them."

The remarks come on a day when American biotechnology company Moderna, Inc, said that its vaccine candidate against COVID-19 has shown 94.5 per cent efficiency.

The WHO chief mentioned that: "Initial supply of COVID19 vaccines will be limited, so healthworkers, older people & other at-risk populations will be prioritised. That will hopefully reduce the number of deaths & enable health systems to cope, but the virus will still have a lot room to move."

Moderna's study, known as the COVE study, enrolled more than 30,000 participants in the U.S. and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID).

This first interim analysis was based on 95 cases, of which 90 cases of COVID-19 were observed in the placebo group versus 5 cases observed in the mRNA-1273 group, resulting in a point estimate of vaccine efficacy of 94.5% (p <0.0001).

Welcoming the progress, Stéphane Bancel, Chief Executive Officer of Moderna, said: “This is a pivotal moment in the development of our COVID-19 vaccine candidate. Since early January, we have chased this virus with the intent to protect as many people around the world as possible. This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease."

Bancel said, “This milestone is only possible because of the hard work and sacrifices of so many."
 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.